Quarterly ResultApr 30, 2026, 06:12 AM
GKOS Q1 Net Sales +41.2% to $150.6M; Net Loss $(19.8)M
AI Summary
GLAUKOS Corp reported a significant increase in net sales for Q1 2026, rising 41.2% to $150.6 million, though the company recorded a net loss of $(19.8) million. The company also announced the assignment of a unique J-code for its Epioxa product, effective July 1, 2026, which is expected to streamline billing and reimbursement. Additionally, Glaukos entered into an option agreement to potentially license proprietary technology or acquire a biopharmaceutical company.
Key Highlights
- Net sales increased 41.2% to $150.6 million in Q1 2026 from $106.7 million in Q1 2025.
- Reported a net loss of $(19.8) million in Q1 2026, compared to $(18.1) million in Q1 2025.
- Basic and diluted net loss per share was $(0.34) in Q1 2026, up from $(0.32) in Q1 2025.
- Gross profit rose 42.4% to $117.2 million in Q1 2026 from $82.3 million in Q1 2025.
- Selling, general and administrative expenses increased 31.5% to $92.9 million.
- Research and development expenses increased 36.5% to $44.1 million.
- CMS assigned a permanent J-code (J2789) for Epioxa, effective July 1, 2026.
- Entered an Option Agreement for proprietary technology license or acquisition for up to $17.5 million upfront.